Wojciech Janowski

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion

Constantine S. Tam, Tadeusz Robak, Paolo Ghia et al. · Haematologica · 2020 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong et al. · Blood · 2022 · 60 citations

Medicine, Oncology, Pharmacotherapy +15

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

Jennifer R. Brown, Tadeusz Robak, Paolo Ghia et al. · Blood · 2020 · 36 citations

Medicine, Oncology, Pharmacology +9

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Constantine S. Tam, Tadeusz Robak, Paolo Ghia et al. · Blood · 2019 · 28 citations

Medicine, Oncology, Pharmacology +5

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results

Mazyar Shadman, Talha Munir, Shuo Ma et al. · Journal of Clinical Oncology · 2025 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +17